

# Technology Development Group

### **Request Information**

### **Combination Immunotherapy**

Tech ID: 29677 / UC Case 2015-348-0

#### SUMMARY

UCLA researchers have developed a combination immunotherapy for lung cancer that functions by evoking anti-tumor immune responses in lung cancer patients.

Available Technologies

#### BACKGROUND

Lung cancer is a challenging health problem, claiming more than 1.1 million deaths worldwide annually. Despite incredible medical progress, the long-term survival rate of lung cancer remains low due to the high risk of recurrence. Therefore, immunotherapy which harnesses the immune system to react against tumors can be an attractive approach with potential for long term anti-tumor benefit.

CCL21 (secondary lymphoid chemokine, SLC) is a lymphoid chemokine which, upon binding to the CCR7 gene receptor, functions as a chemo-attractant for mature dendritic, naïve, and memory T cells. PD-L1 (Programmed death receptor-ligand 1) decreases T cell receptormediated proliferation and cytokine production by interacting with PD1 (Programmed cell death protein 1). While CCL21 enhances cellmediated immunity against tumor cells, the PD-L1/PD1 pathway plays a major role in immune evasion of tumor cells.

#### INNOVATION

Dr. Dubinett's group has previously developed an immunotherapy which evokes anti-tumor immune responses in lung cancer patients by intratumoral administration of dendritic cells expressing the CCR7 receptor ligand CCL21. Their recent clinical data shows that the efficacy of this immunotherapy is most prominent in patients with low tumor PD-1L expression level. This result indicates that blocking PD-1L/PD1 pathway in combination with the CCL21 therapy can be a very effective treatment for lung cancer.

#### **APPLICATIONS**

Immunotherapy for PD-1L-positive lung cancer patients.

#### **ADVANTAGES**

- CCL21 has anti-angiogenic activities in addition to its ability to reduce tumor burden
- The combination therapy improves the efficacy of the existing cancer immunotherapies
- > The combination therapy may have therapeutic implications for other types of cancers

#### STATE OF DEVELOPMENT

A phase I clinical trial was carried out using intratumoral injection of CCL21 gene modified autologous dendritic cells in lung cancer. Results from the trial demonstrated that 1) anti-tumor specific immune responses are elicited and correlate with lower PD-L1 expression, and 2) cytotoxic CD8 T cell infiltration into the tumor is induced.

#### **PATENT STATUS**

Country	Туре	Number	Dated	Case
Japan	Issued Patent	7305300	06/30/2023	2015-348
Germany	Issued Patent	60 2015 082 196.3	01/04/2023	2015-348
France	Issued Patent	3215182	01/04/2023	2015-348
United Kingdom	Issued Patent	3215182	01/04/2023	2015-348
United States Of America	Issued Patent	11,236,139	02/01/2022	2015-348

## Contact Our Team



#### CONTACT

UCLA Technology Development Group ncd@tdg.ucla.edu tel: 310.794.0558.



#### **INVENTORS**

Dubinett, Steven M.

Dubinett, Steven M.

#### **OTHER INFORMATION**

KEYWORDS

Lung cancer, immunotherapy,

therapeutics, immunity

#### **CATEGORIZED AS**

Medical

▶ Disease: Cancer

Therapeutics

RELATED CASES

2015-348-0

Published Application

20220162279

05/26/2022 2015-348

#### **RELATED MATERIALS**

Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S, Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity, Clin Cancer Res., 2004.

▶ Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S, Intrapulmonary administration of CCL21 genemodified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma, Cancer Res., 2006.

▶ Lee JM, Garon EB, Lee M-H, Wang G, Schaue D, Baratelli F, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM, PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer, Journal for immunotherapy of cancer, 2014.

**Privacy Notice** 

## Gateway to Innovation, Research and Entrepreneurship

UCLA Technology Development Group 10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095 https://tdg.ucla.edu Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu © 2018 - 2023, The Regents of the University of California Terms of use

